EDITORIAL COMMENT - 24/07/21
Doi : 10.1016/j.urology.2020.11.081
Phoebe A. Tsao 1, Megan E.V. Caram 1, 2, 3, ⁎
1 Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI
2 Institute of Health Policy & Innovation, University of Michigan Medical School, Ann Arbor, MI
3 Veterans Affairs Health Services Research & Development, Center for Clinical Management & Research, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, MI
⁎Address correspondence to: Megan E.V. Caram, M.D., M.Sc., University of Michigan, 300 North Ingalls Building, Ann Arbor, MI 48109-5419University of Michigan300 North Ingalls BuildingAnn ArborMI48109-5419
It's Complicated
Le texte complet de cet article est disponible en PDF.| Acknowledgement of Research Support: Dr. Caram is funded by a Prostate Cancer Foundation Young Investigator Award. |
|
| Conflicts of interest: The authors have no competing interests and nothing to disclose. |
© 2021
Publié par Elsevier Masson SAS.
Vol 153
P. 154 - juillet 2021 Retour au numéro
Article précédent
- A Population-based Study Comparing Outcomes for Patients With Metastatic Castrate Resistant Prostate Cancer Treated by Urologists or Medical Oncologists With First Line Abiraterone Acetate or Enzalutamide
- Dixon T.S. Woon, Antonio Finelli, Douglas C. Cheung, Lisa J. Martin, Shabbir Alibhai, Christopher J.D Wallis, Christina Diong, Refik Saskin, Girish Kulkarni, Neil Fleshner
- AUTHOR REPLY
- Neil Fleshner
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?